Published in Cancer Res on March 01, 2008
TGF-β: duality of function between tumor prevention and carcinogenesis. J Natl Cancer Inst (2014) 2.08
Tgfbr1 haploinsufficiency is a potent modifier of colorectal cancer development. Cancer Res (2009) 1.26
Activation of the ROCK1 branch of the transforming growth factor-beta pathway contributes to RAGE-dependent acceleration of atherosclerosis in diabetic ApoE-null mice. Circ Res (2010) 1.22
Cancer cell proliferation is inhibited by specific modulation frequencies. Br J Cancer (2011) 1.17
CpG island shore methylation regulates caveolin-1 expression in breast cancer. Oncogene (2012) 1.12
MicroRNA Expression Profiling in Clear Cell Renal Cell Carcinoma: Identification and Functional Validation of Key miRNAs. PLoS One (2015) 0.97
Association between TGFBR1*6A and osteosarcoma: a Chinese case-control study. BMC Cancer (2010) 0.94
Candidate gene association studies: successes and failures. Curr Opin Genet Dev (2010) 0.89
TGFBR1 haplotypes and risk of non-small-cell lung cancer. Cancer Res (2009) 0.88
Changes in expression, and/or mutations in TGF-beta receptors (TGF-beta RI and TGF-beta RII) and Smad 4 in human ovarian tumors. J Cancer Res Clin Oncol (2010) 0.87
SMAD4 is a potential prognostic marker in human breast carcinomas. Tumour Biol (2013) 0.86
Oncogene Ras/phosphatidylinositol 3-kinase signaling targets histone H3 acetylation at lysine 56. J Biol Chem (2012) 0.85
Genetic variations in stem cell-related genes and colorectal cancer prognosis. J Gastrointest Cancer (2012) 0.82
Endogenous myoglobin in breast cancer is hypoxia-inducible by alternative transcription and functions to impair mitochondrial activity: a role in tumor suppression? J Biol Chem (2011) 0.81
Reduced expression of Snail decreases breast cancer cell motility by downregulating the expression and inhibiting the activity of RhoA GTPase. Oncol Lett (2013) 0.80
TGFBR1 and cancer susceptibility. Trans Am Clin Climatol Assoc (2014) 0.77
Transforming growth factor β signaling pathway associated gene polymorphisms may explain lower breast cancer risk in western Indian women. PLoS One (2011) 0.77
TGF-β-Dependent Growth Arrest and Cell Migration in Benign and Malignant Breast Epithelial Cells Are Antagonistically Controlled by Rac1 and Rac1b. Int J Mol Sci (2017) 0.75
Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics (2003) 100.88
The integrin alpha v beta 6 binds and activates latent TGF beta 1: a mechanism for regulating pulmonary inflammation and fibrosis. Cell (1999) 11.59
Regulation of the small GTP-binding protein Rho by cell adhesion and the cytoskeleton. EMBO J (1999) 9.76
Growth factors from murine sarcoma virus-transformed cells. Proc Natl Acad Sci U S A (1978) 8.01
Thrombospondin-1 is a major activator of TGF-beta1 in vivo. Cell (1998) 6.44
Human Smad3 and Smad4 are sequence-specific transcription activators. Mol Cell (1998) 5.88
Rho GTPases and cell migration. J Cell Sci (2001) 5.66
MAP kinases and cell migration. J Cell Sci (2004) 4.46
Latent high molecular weight complex of transforming growth factor beta 1. Purification from human platelets and structural characterization. J Biol Chem (1988) 3.98
Rho GTPases are over-expressed in human tumors. Int J Cancer (1999) 3.70
Role of transforming growth factor Beta in human cancer. J Clin Oncol (2005) 3.53
Dual role of the Smad4/DPC4 tumor suppressor in TGFbeta-inducible transcriptional complexes. Genes Dev (1997) 3.33
Determination of GTP loading on Rho. Methods Enzymol (2000) 2.97
Rhotekin, a new putative target for Rho bearing homology to a serine/threonine kinase, PKN, and rhophilin in the rho-binding domain. J Biol Chem (1996) 2.92
Smad4 dependency defines two classes of transforming growth factor {beta} (TGF-{beta}) target genes and distinguishes TGF-{beta}-induced epithelial-mesenchymal transition from its antiproliferative and migratory responses. Mol Cell Biol (2005) 2.41
Rho GTPases in human breast tumours: expression and mutation analyses and correlation with clinical parameters. Br J Cancer (2002) 2.38
Disruption of transforming growth factor beta signaling by a mutation that prevents transphosphorylation within the receptor complex. Mol Cell Biol (1995) 2.08
TbetaR-I(6A) is a candidate tumor susceptibility allele. Cancer Res (1999) 1.99
Anti-RhoA and anti-RhoC siRNAs inhibit the proliferation and invasiveness of MDA-MB-231 breast cancer cells in vitro and in vivo. Mol Ther (2005) 1.95
Somatic acquisition and signaling of TGFBR1*6A in cancer. JAMA (2005) 1.59
The recombinant proregion of transforming growth factor beta1 (latency-associated peptide) inhibits active transforming growth factor beta1 in transgenic mice. Proc Natl Acad Sci U S A (1996) 1.56
Autocrine transforming growth factor-beta signaling mediates Smad-independent motility in human cancer cells. J Biol Chem (2002) 1.50
Smad-binding defective mutant of transforming growth factor beta type I receptor enhances tumorigenesis but suppresses metastasis of breast cancer cell lines. Cancer Res (2004) 1.38
Transforming growth factor-beta promotes invasion in tumorigenic but not in nontumorigenic human prostatic epithelial cells. Cancer Res (2006) 1.36
Production of fibronectin by human epithelial cells in culture. Cancer Res (1979) 1.34
Combined genetic assessment of transforming growth factor-beta signaling pathway variants may predict breast cancer risk. Cancer Res (2005) 1.29
Transformation potential of Ras isoforms correlates with activation of phosphatidylinositol 3-kinase but not ERK. J Biol Chem (2004) 1.28
Structural alterations of transforming growth factor-beta receptor genes in human cervical carcinoma. Int J Cancer (1999) 1.27
ALK5 promotes tumor angiogenesis by upregulating matrix metalloproteinase-9 in tumor cells. Oncogene (2006) 1.19
Is TGFBR1*6A really associated with increased risk of cancer? J Clin Oncol (2005) 1.09
Overexpression of RhoA-GTP induces activation of the Epidermal Growth Factor Receptor, dephosphorylation of focal adhesion kinase and increased motility in breast cancer cells. Exp Cell Res (2005) 1.08
TGF beta-induced focal complex formation in epithelial cells is mediated by activated ERK and JNK MAP kinases and is independent of Smad4. Biol Chem (2005) 1.04
Structural characterization of the latent complex between transforming growth factor beta 1 and beta 1-latency-associated peptide. Biochem J (1996) 0.99
Enhanced intrinsic migration of aggressive breast cancer cells by inhibition of Rac1 GTPase. Biochem Biophys Res Commun (2006) 0.91
The regulatory effect of tamoxifen on fibronectin expression in estrogen-dependent MCF-7 breast carcinoma cells. Oncol Rep (2006) 0.86
Stromal fibronectin staining pattern and metastasizing ability of human breast carcinoma. Cancer Res (1988) 0.82
Angiogenesis and stromal fibronectin expression in invasive breast carcinoma. Int J Oncol (1998) 0.80
Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nat Med (2002) 21.28
Comparison of Beta-value and M-value methods for quantifying methylation levels by microarray analysis. BMC Bioinformatics (2010) 7.78
Discordant protein and mRNA expression in lung adenocarcinomas. Mol Cell Proteomics (2002) 4.56
Germline allele-specific expression of TGFBR1 confers an increased risk of colorectal cancer. Science (2008) 3.16
TGFBR1*6A and cancer risk: a meta-analysis of seven case-control studies. J Clin Oncol (2003) 2.68
Genetic/familial high-risk assessment: breast and ovarian. J Natl Compr Canc Netw (2010) 2.45
Sugar-sweetened beverage, sugar intake of individuals, and their blood pressure: international study of macro/micronutrients and blood pressure. Hypertension (2011) 2.29
TGF-β: duality of function between tumor prevention and carcinogenesis. J Natl Cancer Inst (2014) 2.08
Protein profiles associated with survival in lung adenocarcinoma. Proc Natl Acad Sci U S A (2003) 1.86
Transforming growth factor beta as a therapeutic target in systemic sclerosis. Nat Rev Rheumatol (2009) 1.79
TGF-beta signaling alterations and susceptibility to colorectal cancer. Hum Mol Genet (2007) 1.77
Variants of the adiponectin (ADIPOQ) and adiponectin receptor 1 (ADIPOR1) genes and colorectal cancer risk. JAMA (2008) 1.73
Proteomic analysis of lung adenocarcinoma: identification of a highly expressed set of proteins in tumors. Clin Cancer Res (2002) 1.67
RANTES expression is a predictor of survival in stage I lung adenocarcinoma. Clin Cancer Res (2002) 1.67
Dietary starch intake of individuals and their blood pressure: the International Study of Macronutrients and Micronutrients and Blood Pressure. J Hypertens (2009) 1.61
Somatic acquisition and signaling of TGFBR1*6A in cancer. JAMA (2005) 1.59
Genetic/familial high-risk assessment: breast and ovarian, version 1.2014. J Natl Compr Canc Netw (2014) 1.48
Novel candidate targets of beta-catenin/T-cell factor signaling identified by gene expression profiling of ovarian endometrioid adenocarcinomas. Cancer Res (2003) 1.46
TGFBR1*6A and cancer: a meta-analysis of 12 case-control studies. J Clin Oncol (2004) 1.42
Tgf-beta signaling alterations and colon cancer. Cancer Treat Res (2010) 1.37
Promoter methylation regulates estrogen receptor 2 in human endometrium and endometriosis. Biol Reprod (2007) 1.34
Novel estrogen receptor-alpha binding sites and estradiol target genes identified by chromatin immunoprecipitation cloning in breast cancer. Cancer Res (2007) 1.33
Combined genetic assessment of transforming growth factor-beta signaling pathway variants may predict breast cancer risk. Cancer Res (2005) 1.29
Variants of the adiponectin and adiponectin receptor 1 genes and breast cancer risk. Cancer Res (2008) 1.28
Tgfbr1 haploinsufficiency is a potent modifier of colorectal cancer development. Cancer Res (2009) 1.26
Bayesian analysis of genetic interactions in case-control studies, with application to adiponectin genes and colorectal cancer risk. Ann Hum Genet (2010) 1.23
Molecular signatures in skin associated with clinical improvement during mycophenolate treatment in systemic sclerosis. J Invest Dermatol (2013) 1.19
Clinically relevant subsets identified by gene expression patterns support a revised ontogenic model of Wilms tumor: a Children's Oncology Group Study. Neoplasia (2012) 1.19
Clear cell sarcoma of the kidney: up-regulation of neural markers with activation of the sonic hedgehog and Akt pathways. Clin Cancer Res (2005) 1.18
TGFBR1*6A may contribute to hereditary colorectal cancer. J Clin Oncol (2005) 1.16
Whole-genome sequencing: a step closer to personalized medicine. JAMA (2011) 1.13
The role of the fat mass and obesity associated gene (FTO) in breast cancer risk. BMC Med Genet (2011) 1.12
Rhabdoid tumor: gene expression clues to pathogenesis and potential therapeutic targets. Lab Invest (2010) 1.11
Targeting transforming growth factor-beta signaling. Curr Opin Oncol (2007) 1.11
Overexpression of oncoprotein 18 correlates with poor differentiation in lung adenocarcinomas. Mol Cell Proteomics (2003) 1.11
Amplitude-modulated electromagnetic fields for the treatment of cancer: discovery of tumor-specific frequencies and assessment of a novel therapeutic approach. J Exp Clin Cancer Res (2009) 1.10
Caring for patients with cancer. JAMA (2010) 1.07
Transcriptional diversity during monocyte to macrophage differentiation. Immunol Lett (2008) 1.06
Contribution of resistance-nodulation-division efflux pump operon smeU1-V-W-U2-X to multidrug resistance of Stenotrophomonas maltophilia. Antimicrob Agents Chemother (2011) 1.03
Polymorphisms of ADIPOQ and ADIPOR1 and prostate cancer risk. Metabolism (2011) 1.02
Role of TGF-beta in cancer and the potential for therapy and prevention. Expert Rev Anticancer Ther (2004) 0.98
Proteomic analysis of cytokeratin isoforms uncovers association with survival in lung adenocarcinoma. Neoplasia (2002) 0.98
No major association between TGFBR1*6A and prostate cancer. BMC Genet (2004) 0.98
Antitransforming growth factor-beta therapy in fibrosis: recent progress and implications for systemic sclerosis. Curr Opin Rheumatol (2008) 0.97
Visual presentation as a welcome alternative to textual presentation of gene annotation information. Adv Exp Med Biol (2010) 0.97
Genetic/familial high-risk assessment: breast and ovarian. J Natl Compr Canc Netw (2006) 0.97
Somatic acquisition of TGFBR1*6A by epithelial and stromal cells during head and neck and colon cancer development. Hum Mol Genet (2007) 0.92
Role of polymorphisms in Adamantiades-Behçet's disease. J Rheumatol (2008) 0.91
No association of TGFB1 L10P genotypes and breast cancer risk in BRCA1 and BRCA2 mutation carriers: a multi-center cohort study. Breast Cancer Res Treat (2008) 0.90
SNAPIN: an endogenous Toll-like receptor ligand in rheumatoid arthritis. Ann Rheum Dis (2012) 0.90
Differential regulation of early growth response gene-1 expression by insulin and glucose in vascular endothelial cells. Arterioscler Thromb Vasc Biol (2003) 0.90
Upregulation of mir-221 and mir-222 in atypical teratoid/rhabdoid tumors: potential therapeutic targets. Childs Nerv Syst (2009) 0.90
Association between IL6 -174G/C and cancer: A meta-analysis of 105,482 individuals. Exp Ther Med (2012) 0.89
Tgfbr1 haploinsufficiency inhibits the development of murine mutant Kras-induced pancreatic precancer. Cancer Res (2009) 0.89
TGF-beta signaling alterations in cancer. Cancer Treat Res (2003) 0.88
Subsets of very low risk Wilms tumor show distinctive gene expression, histologic, and clinical features. Clin Cancer Res (2009) 0.88
TGFBR1 haplotypes and risk of non-small-cell lung cancer. Cancer Res (2009) 0.88
A two-SNP IL-6 promoter haplotype is associated with increased lung cancer risk. J Cancer Res Clin Oncol (2012) 0.87
Identification of estrogen-responsive genes involved in breast cancer metastases to the bone. Clin Exp Metastasis (2007) 0.87
Colorectal Cancer Screening Clinical Practice Guidelines. J Natl Compr Canc Netw (2006) 0.86
New insights into breast cancer genetics and impact on patient management. Curr Treat Options Oncol (2007) 0.86
SMAD4 is a potential prognostic marker in human breast carcinomas. Tumour Biol (2013) 0.86
Mediators of receptor tyrosine kinase activation in infantile fibrosarcoma: a Children's Oncology Group study. J Pathol (2012) 0.85
Differential effects of aspirin before and after diagnosis of colorectal cancer. JAMA (2013) 0.84
Metabolomic characterization of laborers exposed to welding fumes. Chem Res Toxicol (2012) 0.84
Proteomic analysis of eIF-5A in lung adenocarcinomas. Proteomics (2003) 0.83
TGFBR1 signaling and breast cancer. J Mammary Gland Biol Neoplasia (2011) 0.83
Is C-reactive protein an inflammation opsonin that signals colon cancer risk? JAMA (2004) 0.83
Differential gene expression of soluble CD8+ T-cell mediated suppression of HIV replication in three older children. J Med Virol (2011) 0.82
Paracrine-stimulated gene expression profile favors estradiol production in breast tumors. Mol Cell Endocrinol (2006) 0.82
MicroRNA expression profiling for molecular classification of pediatric brain tumors. Pediatr Blood Cancer (2011) 0.81
Meta-analysis based variable selection for gene expression data. Biometrics (2014) 0.80
A Parallel Study of mRNA and microRNA Profiling of Peripheral Blood in Young Adult Women. Front Genet (2011) 0.80
An inducible fusaric acid tripartite efflux pump contributes to the fusaric acid resistance in Stenotrophomonas maltophilia. PLoS One (2012) 0.80
Aspirin--from prevention to targeted therapy. N Engl J Med (2012) 0.80
Transforming Growth Factor Beta and breast cancer. Cancer Treat Res (2005) 0.80
Pilot study of etanercept in patients with refractory juvenile dermatomyositis. Arthritis Care Res (Hoboken) (2014) 0.78
Targeted treatment of cancer with radiofrequency electromagnetic fields amplitude-modulated at tumor-specific frequencies. Chin J Cancer (2013) 0.78
Familial colorectal cancer: a genetics treasure trove for medical discovery. JAMA (2008) 0.78
Study of the gene expression and microRNA expression profiles of malignant rhabdoid tumors originated in the brain (AT/RT) and in the kidney (RTK). Childs Nerv Syst (2013) 0.77
Imatinib mesylate causes genome-wide transcriptional changes in systemic sclerosis fibroblasts in vitro. Clin Exp Rheumatol (2012) 0.77
Potential of whole-genome sequencing for determining risk and personalizing therapy: focus on AML. Expert Rev Anticancer Ther (2012) 0.77
Genetics and genomics for clinicians. JAMA (2008) 0.76
Lack of achievement of a full score on the childhood myositis assessment scale by healthy four-year-olds and those recovering from juvenile dermatomyositis. Arthritis Care Res (Hoboken) (2013) 0.76
A new strategy in the war on renal cell cancer: hitting multiple targets with limited collateral damage. JAMA (2006) 0.76
Pulmonary function tests in idiopathic inflammatory myopathy: association with clinical parameters in children. Arthritis Care Res (Hoboken) (2013) 0.76
Targeting non-small cell lung cancer with epidermal growth factor tyrosine kinase inhibitors: where do we stand, where do we go. Crit Rev Oncol Hematol (2004) 0.75
One step forward toward identification of the genetic signature of glioblastomas. JAMA (2009) 0.75
Inflammatory expression profiles in monocyte-to-macrophage differentiation in patients with systemic lupus erythematosus and relationship with atherosclerosis. Arthritis Res Ther (2014) 0.75
Use of gene signatures to improve risk estimation in cancer. JAMA (2008) 0.75
Genetics and genomics: a call for papers. Arch Surg (2007) 0.75
The cover. Physichromie no. 965. JAMA (2010) 0.75